Published online Aug 26, 2020. doi: 10.4252/wjsc.v12.i8.721
Peer-review started: May 6, 2020
First decision: May 15, 2020
Revised: May 21, 2020
Accepted: August 1, 2020
Article in press: August 1, 2020
Published online: August 26, 2020
Coronavirus disease-2019 (COVID-19) has affected more than 200 countries worldwide. This disease has hugely affected healthcare systems as well as the economy to an extent never seen before. To date, COVID-19 infection has led to about 165000 deaths in 150 countries. At present, there is no specific drug or efficient treatment for this disease. In this analysis based on evidential relationships of the biological characteristics of MSCs, especially umbilical cord (UC)-derived MSCs as well as the first clinical trial using MSCs for COVID-19 treatment, we discuss the use of UC-MSCs to improve the symptoms of COVID-19 in patients.
Core tip: Based on the biological characteristics of mesenchymal stem cells (MSCs), especially umbilical cord (UC)-derived MSCs, and the first clinical trial using MSCs for coronavirus disease-2019 (COVID-19) treatment, we discuss the use of UC-MSCs to improve COVID-19 symptoms. UC-MSCs are suitable therapeutic candidates for COVID-19. Indeed, they are the strongest immunomodulatory MSCs and exhibit low immunogenicity compared with bone marrow-derived MSCs, adipose tissue-derived MSCs, and other MSCs. UC-MSCs are easily collected and expanded in vitro with minimal ethical concerns. In summary, UC-MSCs can be used to improve symptoms in patients with severe COVID-19 by suppressing inflammation and stimulating wound healing.